The MSKCC Score for Metastatic Renal Cell Carcinoma, also known as the Memorial Sloan Kettering Cancer Center Prognostic Score, is a clinical tool used to predict survival in patients with metastatic renal cell carcinoma (mRCC). This scoring system is based on five clinical and laboratory parameters: Karnofsky performance status, time from diagnosis to systemic treatment, lactate dehydrogenase (LDH) levels, hemoglobin levels, and corrected serum calcium levels.
The MSKCC score stratifies patients into three risk groups (favorable, intermediate, and poor) based on the number of risk factors present. This helps clinicians to predict the prognosis of patients with mRCC and guide treatment decisions.
The MSKCC score is specifically designed for patients with metastatic renal cell carcinoma and should not be used in patients with localized disease or other types of kidney cancer. It also may not be applicable in patients with significant comorbidities or those who have received prior systemic therapy for mRCC.
Reference
R J Motzer, M Mazumdar, J Bacik et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999 Aug;17(8):2530-40.
Open reference URL